Description
Release form
Syrup.
Packing
100 ml.
Pharmacological action
Orvirem – an antiviral drug.
Rimantadine, an adamantane derivative, is active against various strains of the influenza A virus (especially type A2). Being a weak base, rimantadine acts by increasing the pH of endosomes, having a vacuole membrane and surrounding viral particles after they enter the cell.
The prevention of acidification in these vacuoles blocks the fusion of the viral envelope with the endosome membrane, thus preventing the transmission of viral genetic material to the cytoplasm of the cell. Rimantadine also inhibits the release of viral particles from the cell, i.e. interrupts the transcription of the viral genome.
The administration of rimantadine within 2-3 days before and 6-7 hours after the onset of clinical manifestations of type A influenza reduces the incidence, severity of disease symptoms and the degree of serological reaction. Some therapeutic effect may also occur if rimantadine is prescribed within 18 hours after the onset of the first symptoms of influenza.
Indications
– Prevention and early treatment of influenza A in children older than 1 year.
Prophylaxis with rimantadine can be effective in contact with patients at home, with the spread of infection in closed groups, and at high risk of the disease during an influenza epidemic.
Contraindications
– acute liver disease
– acute and chronic kidney disease
– thyrotoxicosis
– pregnancy
– lactation period
– children under 1 year of age
– hypersensitivity to the components of the drug Orvrem.
Caution is advised to prescribe the drug for epilepsy (including a history of).
Special instructions
While taking the drug Orvire, an exacerbation of chronic concomitant diseases is possible.
Epilepsy increases the risk of developing an epileptic seizure.
Orvireme Syrup contains 60% sucrose, what should be considered when prescribing the drug to patients with diabetes mellitus.
Possible drug-resistant viruses.
Composition
5 ml (1 teaspoon):
– rimantadine hydrochloride 10 mg
Excipients:
sugar,
sodium alginate,
dye E122,
purified water.
Dosage and administration of
During treatment, the drug Orvirem is taken orally (after eating) with water, according to the following scheme:
– for children from 1 year to 3 years – on the 1st day 10 ml (2 teaspoons) of syrup (20 mg) 3 times / day. (daily dose – 60 mg) on the 2nd and 3rd days – 10 ml 2 times / day. (daily dose – 40 mg), on the 4th day – 10 ml 1 time / day. (daily dose – 20 mg)
– for children from 3 to 7 years – on the 1st day -15 ml (3 teaspoons) of syrup (30 mg) 3 times / day. (daily dose – 90 mg) on the 2nd and 3rd days – 3 teaspoons 2 times / day. (daily dose – 60 mg), on the 4th day – 3 teaspoons 1 time / day. (daily dose – 30 mg).
For prevention, the drug Orvirem is prescribed:
– for children from 1 year to 3 years – 10 ml (2 teaspoons) of syrup (20 mg) 1 time / day.
– for children from 3 to 7 years old – 15 ml (3 teaspoons) of syrup (30 mg) 1 time / day. within 10-15 days depending on the focus of infection.
The daily dose of rimantadine should not exceed 5 mg / kg body weight.
Side effects
The drug Orvire is usually well tolerated. The following adverse reactions are sometimes observed.
From the digestive system: nausea, vomiting, epigastric pain, flatulence, anorexia.
From the side of the central nervous system: headache, dizziness, insomnia, neurological reactions, impaired concentration.
Other: hyperbilirubinemia, allergic reactions (skin rash, itching, urticaria), asthenia.
Drug Interactions
When used together, Orvirem® reduces the effectiveness of antiepileptic drugs.
When taken simultaneously, adsorbents, astringents and enveloping agents reduce the absorption of rimantadine.
Urine acidifying drugs (acetazolamide, sodium bicarbonate) increase the effectiveness of rimantadine due to a decrease in its excretion by the kidneys.
With the combined use of acetylsalicylic acid, paracetamol reduces the Cmax value of rimantadine by 11%.
Cimetidine reduces rimantadine clearance by 18%.
Overdose
No overdose has been detected so far.
Active ingredient
Rimantadine
Terms
pharmacy leave with prescription
Form of Treatment
simply entails dlya accepts vnutry
Indications
Prevention hryppa, Hrypp
Corporation Olifen, Russia
